alexa Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS) | OMICS International
ISSN: 2155-9562
Journal of Neurology & Neurophysiology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS)

Sabrina Paganoni1,2, Erin McDonnell3, David Schoenfeld3, Hong Yu1, Jing Deng1, Hamza Atassi1, Alexander Sherman1, Padmaja Yerramilli-Rao1, Merit Cudkowicz1 and Nazem Atassi1*

1Department of Neurology, Neurological Clinical Research Institute (NCRI), Massachusetts General Hospital; Harvard Medical School, USA

2Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, USA

3Massachusetts General Hospital Biostatistics Center, Boston, MA, USA

*Corresponding Author:
Nazem Atassi
Harvard Medical School
Neurological Clinical Research Institute (NCRI)
Massachusetts General Hospital, 55 Fruit Street
Bigelow 1256, Boston, MA 02114, USA
Tel: (617) 643-1807
Fax: (617) 724-7290
E-mail: [email protected]

Received date: March 24, 2017; Accepted date: April 26, 2017; Published date: April 29, 2017

Citation: Paganoni S, McDonnell E, Schoenfeld D, Yu H, Deng J, et al. (2017) Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). J Neurol Neurophysiol 8:423. doi:10.4172/2155-9562.1000423

Copyright: ©2017 Paganoni S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Neurology & Neurophysiology


Objective: To determine the relationships between hopelessness, depression, quality of life, and disease progression in ALS. Methods: Hopelessness and depression were assessed prospectively in a cohort of people with ALS using the Beck Hopelessness scale (BHS) and the ALS Depression Inventory (ADI-12), respectively. ALS Specific Quality of Life and measures of functional status (ALSFRS-R and forced vital capacity) were collected. Associations between changes in psychological health and functional scores were calculated using Spearman correlation coefficients. Results: Twenty-five people with ALS had at least 2 visits and were followed for a mean of 11 (± 6) months. People with hopelessness and depression reported worse quality of life (p<0.01 for both associations). Decline in function between any two visits measured by ALSFRS-R (p<0.01) and FVC (p=0.02) correlated with increased hopelessness, but not depression. Conclusion: This study highlights the importance of monitoring hopelessness in ALS, particularly in patients with faster functional decline.


Hopelessness; Depression; Quality of life; Predictor; Disease progression


People with amyotrophic lateral sclerosis (ALS) face enormous physical and emotional challenges. It is therefore expected for ALS to have a psychological impact on patients both at the time of diagnosis and throughout the course of the disease [1-8]. In this study we measured hopelessness and depression prospectively in a cohort of people with ALS and estimated their relationship with the rate of disease progression measured by the ALS functional rating scalerevised (ALSFRS-R) [9] and forced vital capacity (FVC).

Materials and Methods

Study participants

Eligible participants had a diagnosis of possible, laboratorysupported probable, probable, or definite ALS [10]. All eligible patients seen at the Massachusetts General Hospital ALS multidisciplinary clinic between March 2009 and September 2010 were asked to participate. New patients who came to our clinic only for a one-time second-opinion visit were excluded. The study protocol was approved by the Institutional Review Board (IRB) at Massachusetts General Hospital.

Study scales

Several scales were administered at study visits that occurred approximately every three months and coincided with their scheduled clinical visits. Hopelessness was assessed using the Beck Hopelessness Scale (BHS), a self-reported series of 20 true-false questions designed to gauge one’s feelings about the future, loss of motivation, and expectations [11]. Depression was measured using the ALS Depression Inventory (ADI-12) [12], a 12-item scale that has been designed to screen for depression in ALS. Quality of life was analyzed using the ALS-specific Quality of Life Questionnaire (ALSSQOL), a 59-item scale that has been designed to assess QOL in ALS [13]. The ALS Functional Rating Scale- Revised (ALSFRS-R) [9] and forced vital capacity (FVC) were also obtained at each study visit. FVC values were expressed as percent of predicted for age, gender, and height.

Statistical analyses

BHS and ADI-12 scores were analyzed as continuous and dichotomous variables. The cut-offs for the dichotomous forms of BHS and ADI-12 were 4 and 23, respectively [11,12]. Changes in BHS, ADI-12, ALSFRS-R and FVC were calculated at each follow-up visit as the difference between the scores at a given visit and the previous visit. Associations between changes in functional scores between two consecutive visits and BHS and ADI-12 scores were calculated using Spearman correlation coefficients, with variances estimated via bootstrapping at the patient level to account for repeated measures. All analyses were performed in SAS version 9.3 (SAS Institute, Cary, NC), using a significance level of 0.05.


Study population

Of 155 eligible patients in our clinic, 36 (23%) agreed to enroll in this longitudinal assessment. Those who chose to participate and those who declined to participate were similar at the time of screening with respect to age, gender, family history of ALS, site of onset, time from symptom onset to diagnosis, time from diagnosis to screening, depression as assessed by ADI-12 scores, antidepressant use and riluzole use (Supplementary Table 1). Among the 36 participants, 25 completed at least 2 and as many as 8 study visits, contributing a total of 79 potential observations for the analyses of associations between changes in mood and function. Participants were followed for a mean of 11 (± 6) months Baseline characteristics of both the overall cohort and the subgroup with follow up data are described in Table 1.

  All Participants N=36 Participants with Available Follow Up Data N=25
  Mean (± SD) or N (%) Mean (± SD) or N (%)
Age at baseline (years) 59.7 (± 11.0) 59.9 (± 11.7)
Gender (% male) 18 (50.0%) 11 (44.0%)
Race (% white) 35 (97.2%) 24 (96.0%)
Marital status (% married) 29 (80.6%) 20 (80.0%)
Any children (%) 30 (83.3%) 23 (92.0%)
Household income (%)    
<$60,000 8 (22.2%) 6 (24.0%)
$60,000-100.000 12 (33.3%) 10 (40.0%)
>$100.000 8 (22.2%) 5 (20.0%)
Missing or Unknown 8 (22.2%) 4 (16.0%)
Familial ALS (%) 4 (11.8%) 2 (8.3%)
Known SOD1 mutation 1 (25.0%) 1 (50.0%)
Bulbar onset (%) 10 (27.8%) 7 (28.0%)
Riluzole use (%) 13 (38.2%) 8 (34.8%)
Antidepressant use (%)* 8 (22.9%) 5 (20.8%)
Time from symptom onset to diagnosis (months) 22.7 (± 35.2) 22.0 (± 38.3)
Time from diagnosis to baseline (months) 24.1 (± 32.8) 19.8 (± 26.2)
ALSFRS-R 32.5 (± 7.8) 33.5 (± 7.5)
FVC 81.7 (± 25.3) 83.7 (± 23.7)
ADI-12 19.8 (± 6.5) 19.6 (± 7.2)
ALSSQOL average score 6.9 (± 1.5) 7.0 (± 1.6)
ALSSQOL religiosity score 4.8 (± 3.9) 5.3 (± 4.0)

Table 1: Baseline clinical and demographic characteristics (ADI-12: ALS Depression Inventory; ALS: Amyotrophic Lateral Sclerosis; ALSFRS-R: ALS Functional Rating Scale; ALSSQOL: ALS-specific Quality of Life; BHS: Beck Hopelessness Scale; FVC: Forced Vital Capacity; *Antidepressant use is defined as any antidepressant prescribed for the specific purpose of treating depression).

Prevalence of hopelessness and depression

At baseline, 59% of study participants were classified as having at least a mild degree of hopelessness and 36% were classified as at least mildly depressed by the ADI-12. Baseline hopelessness, depression and quality of life were all significantly associated, with Spearman correlation coefficients ranging from 0.58 to 0.71 in absolute magnitude (p<0.01 for all associations) (Supplementary Table 2).

Correlation between functional decline, hopelessness and depression

Among patients with available follow up data (N=25), on average, participants declined 2.4 (± 3.4) points on the ALSFRS-R and declined 8.5 (± 15.1) percent in FVC in between 2 visits. Decline in function between two study visits as measured by ALSFRS-R (Figure 1A) and FVC (Figure 1B) correlated with worsening in hopelessness (Spearman correlation coefficient=-0.39, 95% confidence interval (CI) -0.66 to -0.11, p value <0.01 and -0.34, 95% CI -0.66 to -0.03, p value=0.02, respectively). Decline in ALSFRS-R and FVC did not correlate with depression (Spearman correlation coefficient=0.17, 95% CI -0.11 to 0.45, p value=0.89 and -0.11, 95% CI -0.36 to 0.15, p value=0.20, respectively).


Figure 1: Correlation between changes in function and hopelessness. Worsening ALSFRS-R (A) and FVC (B) between two study visits was associated with worsening hopelessness, as measured by BHS scores.


In this study, we found that functional decline correlated with hopelessness but not depression in people with ALS. Hopelessness has been rarely studied in ALS. While hopelessness and depression often co-exist, they are two different constructs. Hopelessness implies negative expectations about the future, pessimism, lack of enthusiasm, and loss of meaning. It is a predictor of negative health outcomes in several populations [14,15]. Of note, hopelessness correlates with interest in physician-assisted suicide [16,17] and predicts suicidal intent and suicide better than depression [18,19].

The lack of correlation between functional decline and depression in this study is consistent with prior ALS studies [1,6,8,20-22]. Depression implies lowered mood and loss of pleasure. It has been speculated that, as disease progresses, the factors that contribute most to mood and pleasure shift from those that are dependent on physical function to those that are not (social, spiritual, and existential factors) [6,21,22], thus explaining the lack of an association between functional decline and depression.


This study includes the small sample size and the possibility of sample bias. Our patients were recruited from the ALS clinic of a large academic center. Attendance at a multidisciplinary clinic has been associated with improved outcomes, including better quality of life [23]. Therefore, the prevalence of psychological distress may be different in the general ALS population. In addition, the follow-up duration was relatively short. Another limitation of our study is that we did not include assessments of cognitive dysfunction. It is now wellrecognized that ALS and frontotemporal dementia (FTD) form a spectrum of disease [24]. We cannot exclude that some of the psychological features identified in our study could be symptoms of mild cognitive impairment.


This study highlights the importance of monitoring hopelessness in ALS, particularly in patients with faster functional decline. While several medications are available to treat depression, how to address hopelessness in ALS has been largely unexplored and warrants further research [23,25].

Individual Authors’ Contributions

Sabrina Paganoni: Analysis/interpretation of data; drafting/revising the manuscript.

Erin McDonnell: Analysis/interpretation of data; drafting/revising the manuscript.

David Schoenfeld: Analysis/interpretation of data; drafting/revising the manuscript.

Hong Yu: Data collection; analysis/interpretation of data.

Jing Deng: Data collection; analysis/interpretation of data.

Hamza Atassi: Data collection; analysis/interpretation of data.

Alexander Sherman: Data collection; analysis/interpretation of data.

PadmajaYerramilli-Rao: Data collection; analysis/interpretation of data.

Merit Cudkowicz: Study concept/design; analysis/interpretation of data; drafting/revising the manuscript.

Nazem Atassi: Study concept/design; analysis/interpretation of data; drafting/revising the manuscript.


Sabrina Paganoni has received funding from the NIH (Career Development Award 2K12HD001097-16), Target ALS, the Salah Foundation, and the Spastic Paraplegia Foundation.

Erin McDonnell reports no disclosures.

David Schoenfeld reports no disclosures.

Hong Yu reports no disclosures.

Jing Deng reports no disclosures.

Hamza Atassi reports no disclosures.

Alexander Sherman receives funding from the AAN, MDA, ALS Association, and ALS Finding a Cure Foundation.

PadmajaYerramilli-Rao is currently employed by Novartis Institutes for BioMedical Research.

Merit Cudkowicz has provided consulting for Neuraltus Pharmaceuticals, Cytokinetics and Teva.

Nazem Atassi receives funding from NINDS, Harvard NeuroDiscovery Center, and ALS Association, and ALS Finding a Cure Foundation and provides consulting for Biogen, Mitsubishi Tanabe, and Denali.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 761
  • [From(publication date):
    April-2017 - May 25, 2018]
  • Breakdown by view type
  • HTML page views : 685
  • PDF downloads : 76

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7